Silo Pharma (SILO) Receivables (2018 - 2023)
Silo Pharma (SILO) posted Receivables of $79200.0 for Q3 2023, up 15.81% sequentially from $68390.0 in Q2 2023.
Silo Pharma (SILO) Receivables (2018 - 2023) Analysis & Trends
Silo Pharma has reported Receivables for 4 years, with the latest figure at $79200.0 in Q3 2023.
- Quarterly Receivables changed N/A year-over-year to $79200.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $79200.0 (changed N/A YoY) and the FY2022 annual result came in at $72020.0, changed N/A from the prior year.
- Receivables improved to $79200.0 in Q3 2023 per SILO's latest filing, from $68390.0 in the prior quarter.
- Over five years, Receivables peaked at $79200.0 in Q3 2023 and troughed at $47000.0 in Q4 2020.
- A 3-year average of $66652.5 and a median of $70205.0 in 2022 frame the typical range for Receivables.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Silo Pharma | 3.04 Mn | 3.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 79,200.00 |
| Jun 30, 2023 | 68,390.00 |
| Dec 31, 2022 | 72,020.00 |
| Dec 31, 2020 | 47,000.00 |
| Sep 30, 2018 | 100,000.00 |